# A Study of SL-325 in Crohn's Disease Patients

> **NCT07753850** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shattuck Labs, Inc.** · enrollment: 232 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** SL-325
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07753850
- **Lead sponsor:** Shattuck Labs, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2028-07
- **Final completion:** 2030-06
- **Target enrollment:** 232 (ESTIMATED)
- **Last updated:** 2026-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07753850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07753850, "A Study of SL-325 in Crohn's Disease Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07753850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*